1.The programmes for the monitoring of transmissible spongiform encephalopathies (TSEs) submitted by Belgium, Bulgaria, the Czech Republic, Denmark, Germany, Estonia, Ireland, Greece, Spain, France, Italy, Cyprus, Latvia, Lithuania, Luxembourg, Hungary, Malta, the Netherlands, Austria, Poland, Portugal, Romania, Slovenia, Slovakia, Finland, Sweden, and the United Kingdom are hereby approved for the period from 1 January 2008 to 31 December 2008.
2.The financial contribution by the Community shall be at the rate of 100 % of the costs to be incurred by each Member State referred to in paragraph 1 for the implementation of those programmes, and shall not exceed:
(a)EUR 1950000 for Belgium;
(b)EUR 850000 for Bulgaria;
(c)EUR 950000 for the Czech Republic;
(d)EUR 1600000 for Denmark;
(e)EUR 9500000 for Germany;
(f)EUR 280000 for Estonia;
(g)EUR 6200000 for Ireland;
(h)EUR 950000 for Greece;
(i)EUR 5500000 for Spain;
(j)EUR 14750000 for France;
(k)EUR 5800000 for Italy;
(l)EUR 450000 for Cyprus;
(m)EUR 350000 for Latvia;
(n)EUR 550000 for Lithuania;
(o)EUR 150000 for Luxembourg;
(p)EUR 700000 for Hungary;
(q)EUR 37000 for Malta;
(r)EUR 2950000 for the Netherlands;
(s)EUR 1400000 for Austria;
(t)EUR 1350000 for Poland;
(u)EUR 2700000 for Portugal;
(v)EUR 1000000 for Romania;
(w)EUR 200000 for Slovenia;
(x)EUR 550000 for Slovakia;
(y)EUR 550000 for Finland;
(z)EUR 1500000 for Sweden;
(za)EUR 5300000 for the United Kingdom.
3.The financial contribution by the Community of the programmes referred to in paragraph 1 shall be for the tests performed and the maximum amount shall not exceed:
(a)EUR 5 per test, for tests carried out in bovine animals referred to in Annex III to Regulation (EC) No 999/2001;
(b)EUR 30 per test, for tests carried out in ovine and caprine animals referred to in Annex III to Regulation (EC) No 999/2001;
(c)EUR 50 per test, for tests carried out in cervid animals referred to in Annex III to Regulation (EC) No 999/2001;
(d)EUR 175 per test, for primary molecular discriminatory tests carried out as referred to in point 3.2(c)(i) of Chapter C of Annex X to Regulation (EC) No 999/2001.